0000899243-19-004728.txt : 20190225 0000899243-19-004728.hdr.sgml : 20190225 20190225173846 ACCESSION NUMBER: 0000899243-19-004728 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190219 FILED AS OF DATE: 20190225 DATE AS OF CHANGE: 20190225 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: JOHNSON KENNETH ERLAND CENTRAL INDEX KEY: 0001743774 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38536 FILM NUMBER: 19630764 MAIL ADDRESS: STREET 1: C/O XERIS PHARMACEUTICALS, INC. STREET 2: 180 N. LASALLE STREET, SUITE 1800 CITY: CHICAGO STATE: IL ZIP: 60601 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: XERIS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001346302 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 203352427 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 180 NORTH LASALLE STREET STREET 2: STE 1800 CITY: CHICAGO STATE: IL ZIP: 60601 BUSINESS PHONE: 512-498-2670 MAIL ADDRESS: STREET 1: 180 NORTH LASALLE STREET STREET 2: STE 1800 CITY: CHICAGO STATE: IL ZIP: 60601 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-02-19 0 0001346302 XERIS PHARMACEUTICALS INC XERS 0001743774 JOHNSON KENNETH ERLAND C/O XERIS PHARMACEUTICALS, INC. 180 N. LASALLE STREET, SUITE 1810 CHICAGO IL 60601 0 1 0 0 See Remarks Common Stock 2019-02-19 4 P 0 1000 10.00 A 3245 D Mr. Johnson purchased shares of common stock from the underwriters in a public offering pursuant to the registrant's Registration Statement on Form S-1 (File No. 333-229665, completed on February 19, 2019). The shares of common stock were purchased at the public offering price. Senior Vice President Clinical Development, Quality Assurance, and Medical Affairs /s/ Beth Hecht 2019-02-25